Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Cardinal (CAH)

Exploring how investors can use the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy in March and throughout what looks set to be a strong 2024.

How to Find Top-Ranked Stocks to Buy in March

Powell Industries

Textron

POWL, CAH and TXT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2023.

Best Growth Stocks to Buy for February 27th

Patria Investments

CAH, POWL and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2024.

Best Growth Stocks to Buy for February 23rd

Builders FirstSource

BLDR and CAH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2024.

Best Value Stocks to Buy for February 23rd

Archrock

J Sainsbury PLC

AROC, JSAIY and CAH made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 23, 2024.

Best Income Stocks to Buy for February 23rd

Central Garden & Pet Company

Iridium Communications

Lantheus Holdings

IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.

New Strong Buy Stocks for February 23rd

American Axle & Manufacturing Hlds

Bread Financial Holdings Inc

Cross Country Healthcare

Deutsche Bank

We believe that stocks like Deutsche Bank (DB), Cross Country Healthcare (CCRN), Bread Financial (BFH), American Axle (AXL) and Cardinal Health (CAH) should be on an investor's watchlist.

5 Stocks Favored by Brokers Amid the Current Uncertainty

Cardinal Health stock is being upgraded to a buy rating, from my prior hold rating last year, agreeing with the SA analyst consensus today. Bullish drivers include recent revenue/earnings growth, expected future EPS growth, a recent business acquisition, competitive edge, and market potential in medical supplies. Some negative factors include a mediocre dividend growth and yield, as well as continuing negative equity.

Cardinal Health: Continued Business Growth And Huge Medical Supplies Market Penetration

Chubb

GlaxoSmithKline

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Leggett & Platt

Mondelez

Altria

PepsiCo

Philip Morris

The markets may swing wildly from week to week and month to month, but dividends are seemingly more stable, reliable and predictable.

DivHut Dividend Income Update: January 2024

Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Canadian Imperial Bank of Commerce

Genuine Parts

Huntington Bancshares

Iron Mountain

Medtronic

National Grid

Realty Income Corp

Orion Office REIT

Paramount Global

TotalEnergies SE

In January 2024, we received $6851.67 in dividend income. Leggett & Platt was the highest dividend payer this month.

Bert's January Dividend Income Summary

American Airlines

Best Buy

Cleveland-Cliffs

Delta Air Lines

We believe that stocks like American Airlines (AAL), Delta Air Lines (DAL), Cleveland-Cliffs (CLF), Best Buy (BBY) and Cardinal Health (CAH) should be on an investor's watchlist.

5 Broker-Loved Stocks to Watch Amid Current Market Swings

DUBLIN, Ohio , Feb. 6, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today released its Fiscal 2023 Environmental, Social and Governance (ESG) Report, highlighting the company's work toward building a healthier, more equitable future. "At Cardinal Health, we approach ESG in a way that supports our business, positions us as a partner of choice for customers and suppliers, and ensures compliance with evolving regulatory requirements," said Jason Hollar, Cardinal Health's CEO.

Cardinal Health publishes Fiscal 2023 Environmental, Social and Governance (ESG) Report

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

Cardinal Health, Inc. (CAH) Q2 2024 Earnings Call Transcript

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Cardinal (CAH) Q2 Earnings: A Look at Key Metrics

Cardinal Health lowered the full-year profit forecast for its medical segment on Thursday, taking the shine off the company's upbeat second-quarter results and sending its shares down more than 5%.

Cardinal Health lowers medical unit profit forecast, shares fall

Cardinal Health (CAH) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.32 per share a year ago.

Cardinal Health (CAH) Tops Q2 Earnings and Revenue Estimates

Revenue increased 12% to $57.4 billion GAAP1 operating earnings were $482 million; GAAP diluted EPS was $1.43 Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS increased 38% to $1.82 Fiscal 2024 non-GAAP EPS guidance raised to $7.20 to $7.35, from $6.75 to $7.00 2,3 Fiscal 2024 non-GAAP adjusted free cash flow guidance raised to ~$2.5 billion, from ~$2.0 billion Cardinal Health to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization DUBLIN, Ohio , Feb. 1, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal 2024 revenue of $57.4 billion, an increase of 12% from the second quarter of last year. Second quarter GAAP operating earnings were $482 million and GAAP diluted earnings per share (EPS) were $1.43.

Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook

Here is how Cardinal Health (CAH) and CSL Limited Sponsored ADR (CSLLY) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

Axonics ModulationTechnologies Inc

Acuity Brands

Enerpac Tool Group Corp

Invest in companies like Axonics (AXNX), Enerpac Tool Group (EPAC), Cardinal Health (CAH) and Acuity Brands (AYI) due to higher efficiency levels.

4 Stocks Backed by High Efficiency to Enrich Your Portfolio

Cardinal Health Inc. CAH, +0.73% announced Wednesday an agreement to buy Specialty Networks for $1.2 billion in cash. Cardinal said the acquisition expands its offering in therapeutic areas by boosting its analytics capabilities and service offerings, and increases its data and research opportunities with biopharmaceutical manufacturers.

Cardinal Health to buy Specialty Networks for $1.2 billion in cash to boost analytics capabilities

Cardinal Health said on Wednesday it will buy Specialty Networks, a private company that provides technological solutions for healthcare organizations, for $1.2 billion in cash.

News for Cardinal Health Stock (CAH)